<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0390">
 <label>17</label>
 <element-citation publication-type="journal" id="sbref0390">
  <person-group person-group-type="author">
   <name>
    <surname>Zinman</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Wanner</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Lachin</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Fitchett</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Bluhmki</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Hantel</surname>
    <given-names>S.</given-names>
   </name>
   <collab>EMPA-REG OUTCOME Investigators</collab>
  </person-group>
  <article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title>
  <source>N Engl J Med.</source>
  <volume>373</volume>
  <year>2015</year>
  <fpage>2117</fpage>
  <lpage>2128</lpage>
  <pub-id pub-id-type="pmid">26378978</pub-id>
 </element-citation>
</ref>
